Repligen (RGEN) is trading higher Tuesday, April 21, 2026, as the market prices in renewed Wall Street optimism following fresh positive coverage and recent rating/price-target actions. A new Buy initiation/coverage note has circulated in the past several sessions, helping lift sentiment into the company’s next earnings event. (marketbeat.com)

The timing is notable because Repligen is approaching its next quarterly earnings report at the end of April, a window when incremental bullish research updates can have an outsized impact on positioning. With investors looking for confirmation that bioprocessing demand is improving, any reinforcement of a recovery narrative can quickly translate into multiple expansion for the group. (benzinga.com)

Repligen’s most recent reported quarter included full-year 2026 guidance calling for revenue of $810 million to $840 million and diluted EPS of $1.93 to $2.01, framing expectations for growth and margin progression this year. Traders are effectively leaning into the view that Repligen can execute through 2026 and benefit if customers resume normal ordering patterns across bioprocessing consumables and tools. (investors.repligen.com)

Key near-term catalysts are the upcoming earnings release and any commentary on order trends, customer inventory digestion, and the pace of recovery across biotech and CDMO spending. If management reiterates or raises 2026 targets, today’s move could extend; if demand signals soften, the stock’s recent run-up could reverse quickly into the print. (benzinga.com)